ClinicalTrials.gg
Status unknownNCT05460429Updated Jan 12, 2023

Immunogenicity, Safety and Protective Effect of Live Attenuated Varicella Vaccine and Study on Antibody Level and Etiology of Varicella Zoster Virus

A Phase 4 interventional study of Live attenuated varicella vaccine in Varicella, sponsored by Sinovac (Dalian) Vaccine Technology Co., Ltd.. Status unknown at 3 sites in China. Open to participants aged Up to 59 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-01-12.

Sponsored by Sinovac (Dalian) Vaccine Technology Co., Ltd. (part of Sinovac Biotech Co., Ltd) · Phase 4, Interventional, and Prevention

The sponsor has not verified this record recently (last verified Apr 2022), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
37,920
Allocation
Non-randomized
Ages
Up to 59 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing Chickenpox Vaccine in Chickenpox — 5 open to participants now, 7 under way, 4 of them phase 3. Chickenpox Vaccine · Chickenpox.

Planned enrollment
3rd of 36
37,920 · median 404
Started
2022
with 2 others
Phase 4
14 of 36
2 open now
Registered
28th of 36
by date
Lead sponsor
11 of 36
Sinovac (Dalian) Vaccine Technology Co., Ltd.

Among the 36 studies testing Chickenpox Vaccine in Chickenpox, this one is the 3rd largest by planned enrollment, is one of 3 that started in 2022, is one of 14 in phase 4, and was the 28th registered.

Chickenpox

180 studies on the registry are indexed under Chickenpox; 28 are open to participants now.

Browse Chickenpox studies →

Open to participants now

5 of the 36 studies testing Chickenpox Vaccine in Chickenpox are open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About Chickenpox Vaccine

Chickenpox Vaccine: first FDA approval 1995 (Varivax). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 16 Chickenpox studies recruiting now, 3 (19%) set no upper age limit and 13 (81%) stop at 75 or younger; 12 take children under 18; 13 take healthy volunteers.

This study: Up to 59 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing Chickenpox Vaccine in Chickenpox, or all of them as a file.
02

Study summary

This is Phase 4 clinical trial of live attenuated varicella vaccines manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd .The purpose of this study is to evaluate the immunogenicity and safety of a single dose of varicella vaccine in healthy children aged 1-6 years with different varicella immunization histories, to evaluate the antibody level of varicella-zoster virus in healthy people aged 0-59 years in Zhejiang Province.

Read the detailed description

This study is Phase Ⅳ clinical trial.The experimental vaccine manufactured by Sinovac(Dalian) Vaccine Technology Co., Ltd.This clinical trial consists of five parts,and A total of 37920 subjects will be enrolled.

Study 1,360 subjects including 120 subjects aged 1-3 years with no history of varicella vaccination ,240 subjects aged 4-6 years with a history of 1 dose of varicella vaccine will be enrolled to evaluate the immunogenicity and safety of varicella vaccine.All subjects will receive one dose of varicella vaccine.

Study 2,2530 subjects aged 0-59 years old will be enrolled and will be collected venous blood to detect varicella antibody and conduct investigation of varicella antibody level in healthy people.

Study 3,30000 subjects aged 1-12 years old will be enrolled to conduct safety observation study.All subjects will receive one dose of varicella vaccine and all adverse events of all subjects will be collected.

Study 4,5000 subjects aged 1-12 years old will be enrolled to conduct protective effect study of varicella vaccine after exposure.

Study 5,30 subjects aged 1-12 years old will be enrolled. Herpes fluid or pharyngeal swab samples of subjects will be collected to study the pathogenicity of varicella.

03

Conditions studied

  • Varicella

Browse trials for

04

Who can participate

Ages eligible
Up to 59 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Unified Inclusion Criteria:

  • Participants aged 1-12 years ;
  • The subjects and/or guardians can understand and voluntarily sign the form (For subjects aged 8-12 years, both subjects and guardians need to sign the informed consent form) and be able to follow all research procedures;
  • Proven legal identity.

Special Inclusion Criteria for each study:

Inclusion criteria of the study population for immunogenicity and safety evaluation of varicella vaccine:

  • Be able to participate in the whole process of vaccination and blood collection;
  • Healthy children aged 1-3 years with no history of varicella vaccination;
  • Healthy children aged 4-6 years with a history of 1 dose of varicella vaccine.

Inclusion criteria for investigation of varicella antibody level:

  • Healthy people aged 0-59 years and participate voluntarily for the study;
  • Have no serious chronic disease or acute disease;

Inclusion criteria of the study population for safety evaluation of varicella vaccine mass vaccination:

  • Participants aged 1-3 years with no history of varicella vaccination;
  • Participants aged 4-12 years with no history of varicella vaccination or with a history of 1 dose of varicella vaccine.

Inclusion criteria of study population for protective effect of varicella vaccine after exposure:

  • Children aged 1-12 years exposed to varicella outbreaks;
  • History with no varicella or shingles;

Inclusion criteria of study population for etiological study on the pathogenic strains of varicella cases:

  • Clinical cases of varicella consent for herpes zoster or pharyngeal swab collection.

Exclusion Criteria:

  • History of 2 doses of varicella vaccination;
  • Previous history of varicella or herpes zoster (not applicable to investigation of varicella antibody level);
  • History of severe allergic reactions to vaccines (e.g.acute anaphylaxis, angioneurotic edema, dyspnea, etc.);
  • Suffering from acute disease or acute episode of chronic disease;
  • Any confirmed or suspected immunodeficiency disease, including (HIV) infection;
  • Axillary temperature >37.0°C;
  • Receipt of other drugs in the past 30 days;
  • Receipt of attenuated in the past 28 days;
  • Receipt of inactivated or subunit vaccines in the past 7 days;
  • According to the investigator's judgment, the subject has any other factors that are not suitable for participating in the clinical trial.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
37,920 participants (estimated)

Study arms

  • Experimental
    Immunogenicity and safety group

    360 subjects including 120 subjects aged 1-3 years with no history of varicella vaccination,240 subjects aged 4-6 years with a history of 1 dose of varicella vaccine will be enrolled to evaluate the immunogenicity and safety of varicella vaccine.All subjects will receive one dose of varicella vaccine.

    Biological: Live attenuated varicella vaccine

  • Experimental
    Antibody level investigation study group

    Immunization levels will be monitored among 2530 subjects aged 0-59 years old and will be collected venous blood to detect varicella antibody.

    Biological: Live attenuated varicella vaccine

  • Experimental
    Safety group

    30000 subjects aged 1-12 years old will be enrolled to conduct safety observation of mass vaccination of varicella vaccine.All subjects will receive one dose of varicella vaccine and all adverse events of all subjects will be collected.

    Biological: Live attenuated varicella vaccine

  • Experimental
    Protective effect group

    5000 subjects aged 1-12 years old will be enrolled to conduct protective effect study of varicella vaccine after exposure.

    Biological: Live attenuated varicella vaccine

  • Experimental
    Etiology Group

    30 varicella cases aged 1-12 years old from study 4 will be enrolled. Herpes fluid or pharyngeal swab samples of subjects will be collected to study the pathogenicity of varicella.

    Biological: Live attenuated varicella vaccine

Interventions

  • The live attenuated varicella vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd. Live attenuated varicella-virus in 0.5 mL injection water with sucrose,sodium glutamate,sodium chloride,potassium chloride, sodium dihydrogen phosphate, potassium dihydrogen phosphate per injection.The routine of administration is intramuscular injection into deltoid region of the lateral upper arm. And the immunization schedule is one dose of live attenuated varicella vaccine on day 0.

06

What researchers measure

Primary outcomes

  1. GMT of varicella antibody in children aged 1-6 years

    GMT of varicella antibody at 30 days after vaccination of varicella vaccine in children aged 1-6 years.

    Time frame: 30 days after vaccination

  2. GMT of varicella antibody in healthy people aged 0-59 years

    GMT of varicella antibody at 30 days after vaccination in different age groups of healthy people aged 0-59 years.

    Time frame: 30 days after vaccination

Secondary outcomes

  1. Seroconversion rates of varicella antibody in children aged 1-6 years

    Seroconversion rates of varicella antibody at 30 days after vaccination of varicella vaccine in children aged 1-6 years.

    Time frame: 30 days after vaccination

  2. GMI of varicella antibody in children aged 1-6 years

    GMI of varicella antibody at 30 days after vaccination of varicella vaccine in children aged 1-6 years.

    Time frame: 30 days after vaccination

  3. Incidence of adverse reactions at 24 hours after vaccination

    Incidence of adverse reactions at 24 hours after vaccination of varicella vaccine in children aged 1-6 years

    Time frame: 24 hours after vaccination

  4. Incidence of adverse reactions at 3 days after vaccination

    Incidence of adverse reactions at 3 days after vaccination of varicella vaccine in children aged 1-6 years

    Time frame: 3 days after vaccination

  5. Incidence of adverse reactions at 14 days after vaccination

    Incidence of adverse reactions at 14 days after vaccination of varicella vaccine in children aged 1-6 years.

    Time frame: 14 days after vaccination

  6. Incidence of adverse reactions at 30 days after vaccination

    Incidence of adverse reactions at 30 days after vaccination of varicella vaccine in children aged 1-6 years.

    Time frame: 30 days after vaccination

  7. Incidence of adverse reactions at 14 days after mass vaccination

    Incidence of adverse reactions at 14 days after mass vaccination of varicella vaccine in children aged 1-12 years

    Time frame: 14 days after mass vaccination

  8. Incidence of adverse reactions at 30 days after mass vaccination

    Incidence of adverse reactions at 30 days after mass vaccination of varicella vaccine in children aged 1-12 years

    Time frame: 30 days after mass vaccination

  9. seropositive rates of varicella antibody

    Seropositive rates of varicella antibody at 30 days after vaccination in all age groups of healthy people.

    Time frame: 30 days after vaccination

07

Study locations

3 of 3 sites recruiting
  • Laian Center for Disease Control and Prevention
    Chuzhou, Anhui 239299, China
    Recruiting
  • Liandu District Center for Disease Control and Prevention
    Lishui, Zhejiang 323050, China
    Recruiting
  • Jiangshan Center for Disease Control and Prevention
    Quzhou, Zhejiang 324199, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2022 (actual). Primary completion is estimated for Mar 2023, 7 months after the start.

Of 14 phase 4 interventional studies under Chickenpox, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 22. This study's planned 7 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 12, 2022
First posted
Jul 15, 2022
StartActual
Jul 30, 2022
Primary completionEst.
Mar 15, 2023
CompletionEst.
May 15, 2023
Last update
Jan 12, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05460429
Responsible party
Sponsor
First posted
Jul 15, 2022
Start date
Jul 30, 2022
Primary completion
Mar 15, 2023 (estimated)
Completion
May 15, 2023 (estimated)
Last update
Jan 12, 2023

Study contacts

Hanqing He, Master
Contact
hanqinghe@cdc.zj.cn
13819483847
Hanqing He
principal investigator · Zhejiang Provincial Center for Disease Prevention and Control

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Chickenpox Vaccine

Start the discussion